MGlu5 negative allosteric modulators: A patent review (2010-2012)

Expert Opinion on Therapeutic Patents

Volumn 23, Issue 4, 2013, Pages 393-408

  Emmitte, Kyle A ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dipraglurant; Dyskinesia; Fragile X syndrome; Glutamate; Mavoglurant; MGlu5; Negative allosteric modulator; Neuroscience; Parkinson's disease; RG7090

Indexed keywords

ADX 10059; ADX 48621; AZD 2066; AZD 2516; AZD 9272; DIPRAGLURANT; FENOBAM; GRN 529; MAVOGLURANT; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; NPL 2009; RASEGLURANT; RG 7090; STX 107; UNCLASSIFIED DRUG;

ADDICTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; AUTISM; CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG INDICATION; DRUG STRUCTURE; DYSKINESIA; FRAGILE X SYNDROME; GASTROESOPHAGEAL REFLUX; HUMAN; MIGRAINE; NEUROPATHIC PAIN; NONHUMAN; PAIN; PARKINSON DISEASE; PATENT; REVIEW; SIDE EFFECT; SMOKING CESSATION;

ALKYNES; ANIMALS; BINDING SITES; DRUG AND NARCOTIC CONTROL; DRUG DESIGN; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HUMANS; MOLECULAR STRUCTURE; PATENTS AS TOPIC; RECEPTOR, METABOTROPIC GLUTAMATE 5; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84875192840     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.760544     Document Type: Review

References (131)

1. Schoepp DD, Jane DE, Monn JA. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999;38:1431-76
2. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 1997;37:205-37
3. Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5:993-6
4. Wise A, Gearing K, Rees S. Target validation of G-protein coupled receptors. Drug Discov Today 2002;7:235-46
5. Knopfel T, Kuhn R, Allgeier H. Metabotropic glutamate receptors: novel targets for drug development. J Med Chem 1995;38:1417-26
6. Melancon BJ, Hopkins CR, Wood MR, et al. Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery. J Med Chem 2012;55:1445-64
7. Conn PJ, Christopolous A, Lindsley CW. Allosteric modulators of GPCRs as a novel approach to treatment of CNS disorders. Nat Rev Drug Discov 2009;8:41-54
8. Bridges TM, Lindsley CW. G-protein coupled receptors: from classical modes of modulation to allosteric mechanisms. ACS Chem Biol 2008;3:530-42
9. Niswender CM, Jones CK, Conn PJ. New therapeutic frontiers for metabotropic glutamate receptors. Curr Top Med Chem 2005;5:847-57
10. Ritzen A, Mathiesen JM, Thomsen C. Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators. Basic Clin Pharmacol Toxicol 2005;97:202-13
11. Kew JNC. Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential. Pharmacol Ther 2004;104:233-44
12. Emmitte KA. Recent advances in the design and development of novel negative allosteric modulators of mGlu5. ACS Chem Neurosci 2011;2:411-32
13. Rocher JP, Bonnet B, Bolea C, et al. mGluR5 negative allosteric modulators overview: a medicinal chemistry approach towards a series of novel therapeutics. Curr Top Med Chem 2011;11:680-95
14. Lindsley CW, Emmitte KA. Recent progress in the discovery and development of negative allosteric modulators of mGluR5. Curr Opin Drug Discov Devel 2009;12:446-57
15. Gasparini F, Bilbe G, Gomez-Mancilla B, Spooren W. mGluR5 antagonists: discovery, characterization and drug development. Curr Opin Drug Discov Devel 2008;11:655-65
16. Jaeschke G, Wettstein JG, Nordquist RE, Spooren W. mGlu5 receptor antagonists and their therapeutic potential. Expert Opin Ther Pat 2008;18:123-42
17. Rodriguez AL, Williams R. Recent progress in the development of allosteric modulators of mGluR5. Curr Opin Drug Discov Devel 2007;10:715-22
18. Gasparini F, Lingenhohl K, Stoehr N, et al. Methyl-6-(phenylethynyl)- pyridine (MPEP), a potent, selective and systematically active mGlu5 receptor antagonist. Neuropharmacology 1999;38:1493-503
19. Cosford ND, Tehrani L, Roppe J, et al. 3-[(2-Methyl-1,3-thiazol-4-yl) ethynyl]- pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem 2003;46:204-6
20. Zhu CZ, Wilson SG, Mikusa JP, et al. Assessing the role of metabotropic glutamate receptor 5 in multiple nociceptive modalities. Eur J Pharmacol 2004;506:107-18
21. Pietraszek M, Sukhanov I, Maciejak P, et al. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur J Pharmacol 2005;514:25-34
22. Busse CS, Brodkin J, Tattersall D, et al. The behavioral profile of the potent and selective mGlu5 receptor antagonist 3- [(2-methyl-1,3-thiazol-4-yl) ethynyl]- pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 2004;29:1971-9
23. Klodzinska A, Tatarczynska E, Chojnacka-Wojcik E, et al. Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABAA signaling. Neuropharmacology 2004;47:342-50
24. Spooren WPJM, Vassout A, Neijt HC, et al. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6- (phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 2000;295:1267-75
25. Nicolas LB, Kolb Y, Prinssen EPM. A combined marble burying-locomoter activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants. Eur J Pharmacol 2006;547:106-15
26. Jensen J, Lehmann A, Uvebrant A, et al. Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist. Eur J Pharmacol 2005;519:154-7
27. Frisby CL, Mattsson JP, Jensen JM, et al. Inhibition of transient lower esophageal sphincter relaxtation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology 2005;129:995-1004
28. Morin N, Gregoire L, Gomez-Mancilla B, et al. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 2010;58:981-6
29. de Vrij FMS, Levenga J, van der Linde HC, et al. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 2008;31:127-32
30. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 2005;49:1053-66
31. Lindemann L, Jaeschke G, Michalon A, et al. CTEP: A novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. J Pharmacol Exp Ther 2011;339:474-86
32. Michalon A, Sidorov M, Ballard TM, et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 2012;74:49-56
33. Silverman JL, Tolu SS, Barkan CL, Crawley JN. Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. Neuropsychopharmacology 2010;35:976-89
34. Silverman JL, Smith DG, Sukoff Rizzo SJ, et al. Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci Transl Med 2012;4:131ra51
35. McGeehan AJ, Olive MF. The mGluR5 antagonist MPEP reduces the conditioned rewarding effects of cocaine but not other drugs of abuse. Synapse 2003;47:240-2
36. Chiamulera C, Epping-Jordan MP, Zocchi A, et al. Reinforcing and locomoter stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat Neurosci 2009;4:873-4
37. Martin-Fardon R, Baptista MAS, Dayas CV, Weiss F. Dissociation of the effects of MTEP [3-[(2-methyl-1,3- thiazol-4-yl)ethynyl]pyridine] on conditioned reinstatement and reinforcement: comparison between cocaine and a conventional reinforcer. J Pharmacol Exp Ther 2009;329:1084-90
38. Kumaresan V, Yuan M, Yee J, et al. Metabotropic glutamate receptor 5 (mGluR5) antagonists attenuate cocaine priming- and cue-induced reinstatement of cocaine seeking. Behav Brain Res 2009;202:238-44
39. Backstrom P, Hyytia P. Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking. Neuropsychopharmacology 2006;31:778-86
40. Iso Y, Grajkowska E, Wroblewski JT, et al. Synthesis and structure-activity relationships of 3-[(2-methyl-1,3-thiazol- 4-yl)ethynyl]pyridine analogues as potent, noncompetitive metabotropic glutamate receptor subtype 5 antagonists; search for cocaine medications. J Med Chem 2006;49:1080-100
41. Kenny PJ, Boutrel B, Gasparini F, et al. Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats. Psychopharmacology (Berl) 2005;179:247-54
42. Tessari M, Pilla M, Andreoli M, et al. Antagonism at metabotropic glutamate 5 receptor inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking. Eur J Pharmacol 2004;499:121-33
43. Platt DM, Rowlett JK, Spealman RD. Attenuation of cocaine self-administration in squirrel monkeys following repeated administration of the mGluR5 antagonist MPEP: comparison with dizocilpine. Psychopharmacology (Berl) 2008;200:167-76
44. Lee B, Platt DM, Rowlett JK, et al. Attenuation of behavioral effects of cocaine by the metabotropic glutamate receptor 5 antagonist 2-methyl-6- (phenylethynyl)-pyridine in squirrel monkeys: comparison with dizocilpine. J Pharmacol Exp Ther 2005;312:1232-40
45. Tronci V, Vronskaya S, Montgomery N, et al. The effects of the mGluR5 receptor antagonist 6-methyl-2-(phenylethynyl)- pyridine (MPEP) on behavioural responses to nicotine. Psychopharmacology (Berl) 2010;211:33-42
46. Kotlinska J, Bochenski M. Comparison of the effects of mGluR1 and mGluR5 antagonists on the expression of behavioral sensitization to the locomotor effect of morphine and the morphine withdrawal jumping in mice. Eur J Pharmacol 2007;558:113-18
47. Gass JT, Osborne MPH, Watson NL, et al. mGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine- seeking behavior in rats. Neuropsychopharmacology 2009;34:820-33
48. Adams CL, Short JL, Lawrence AJ. Cue-conditioned alcohol seeking in rats following abstinence: involvement of metabotropic glutamate 5 receptors. Br J Pharmacol 2010;159:534-42
49. Besheer J, Grondin JJM, Salling MC, et al. Interoceptive effects of alcohol require mGlu5 receptor activity in the nucleus accumbens. J Neurosci 2009;29:9582-91
50. Gass JT, Olive MF. Role of protein kinase C epsilon (PKCepsilon) in the reduction of ethanol reinforcement due to mGluR5 antagonism in the nucleus accumbens shell. Psychopharmacology (Berl) 2009;204:587-97
51. Schroeder JP, Spanos M, Stevenson JR, et al. Cue-induced reinstatement of alcohol-seeking behavior is associated with increased ERK1/2 phosphorylation in specific limbic brain regions: blockade by the mGluR5 antagonist MPEP. Neuropharmacology 2008;55:546-54
52. Lominac KD, Kapasova Z, Hannun RA, et al. Behavioral and neurochemical interactions between group 1 mGluR antagonists and ethanol: potential insight into their anti-addictive properties. Drug Alcohol Depend 2006;85:142-56
53. Hughes ZA, Neal SJ, Smith DL, et al. Negative allosteric modulation of metabolic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression. Neuropharmacology 2012;doi:10.1016/j. neuropharm.2012.04.007
54. Pecknold JC, McClure DJ, Appeltauer L, et al. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J Clin Psychopharmacol 1982;2:129-32
55. Structure of fenobam disclosed in Porter RHP, Jaeschke G, Spooren W, et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 315:711-21
56. Berry-Kravis EM, Hessl D, Coffey S, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 2009;46:266-71
57. Autism Therapeutics Press Release. Autism therapeutics announces purchase of Neuropharm Ltd. New York: 2011. Available from: http://www. autismtherapeutics.com/?p=238
58. Raseglurant structure disclosed in International nonproprietary names for pharmaceutical substances (INN). WHO Drug Information 2009;23:339-40
59. Keywood C, Wakefield M, Tack J. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastroesophageal reflux disease. Gut 2009;58:1192-9
60. Marin JCA, Goadsby PJ. Glutamatergic fine tuning with ADX-10059: a novel therapeutic approach for migraine? Exp Opin Investig Drugs 2010;19:555-61
61. Addex Pharmaceuticals Press Release. Development of ADX10059 ended for long-term use. Geneva: 2011. Available from: http://www. addextherapeutics.com/ investors/press-releases/
62. Dipraglurant structure disclosed in International nonproprietary names for pharmaceutical substances (INN). WHO Drug Information 2009;23:328
63. Addex Pharmaceuticals Press Release. Addex ADX48621 positive primate Parkinson's data. Geneva: 2009. Available from: http://www. addextherapeutics. com/investors/press-releases/
64. Addex Pharmaceuticals Press Release. Addex reports positive top line phase IIa data for dipraglurant in Parkinson's disease levodopa-Induced dyskinesia (PDLID). Geneva: 2012. Available from: http://www.addextherapeutics. com/investors/press-releases/
65. Mavoglurant structure disclosed in International nonproprietary names for pharmaceutical substances (INN). WHO Drug Information 2010;24:381
66. Berg D, Godau J, Trenkwalder C, et al.056 treatment of levodopa-induced dyskinesias: results of 2 randomized clinical trials. Mov Disord 2011;26:1243-50
67. Gregoire L, Morin N, Ouattara B, et al. The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. Parkinsoniam Rel Disord 2011;17:270-6
68. Jacquemont S, Curie A, des Portes V, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 2011;3:64ra1
69. RG7090 structure. Available from: http://www.accessdata.fda.gov/scripts/ opdlisting/oopd/OOPD-Results-2.cfm? Index-Number=333211
70. STX107 structure disclosed in reference 125
71. Raboisson P, Breitholtz-Emanuelsson A, Dahllof H, et al. Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development. Bioorg Med Chem Lett 2012;22:6974-9
72. Rohof WO, Lei A, Hirsch DP, et al. The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers. Ailment Pharmacol Ther 2012;35:1231-42
73. Stahle L, Karlsten R, Jonzon B, et al. Safety evaluation of the mGluR5 antagonists AZD9272, AZD2066 and AZD2516 in healthy volunteers and patients with neuropathic pain or major depressive disorders [Abstract PT444]. Abstracts of Papers: 14th World Congress on Pain. 28 August 2012; Milan, Italy
74. Novartis AG. 4-Tolyl-ethynyl-octahydroindole- 1-ester derivatives. WO101058; 2012
75. Novartis AG. 4-(Hetero)aryl-ethynyloctahydro- indole-1-carboxylic acid esters. WO084873; 2012
76. Daggett LP, Sacaan AI, Akong M, et al. Molecular and functional characterization of recombinant human metabotropic glutamate receptor subtype 5. Neuropharmacol 1995;34:871-86
77. Novartis AG. Combination Products. WO000763; 2010
78. Novartis AG. Combinations of alpha 7 nicotinic acetylcholine receptor activators and mGluR5 antagonists for use in dopamine induced dyskinesia in Parkinson's disease. WO127393; 2012
79. Quik M, Cox H, Parameswaran N, et al. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Ann Neurol 2007;62:588-96
80. Bordia T, Campos C, Huang L, Quik M. Continuous and intermittent nicotine treatment reduces L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease. J Pharmacol Exp Ther 2008;327:239-47
81. Feuerbach D, Nozulak J, Lingenhoehl K, et al. JN403, in vitro characterization of a novel nicotinic acetylcholine receptor alpha7 selective agonist. Neurosci Lett 2007;416:61-5
82. AstraZeneca AB. A new crystalline form of 4-(5-{(1R)-1-[5-(3- chlorophenyl) isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,4- triazol-3-yl)pyridine. WO019100; 2010
83. AstraZeneca AB. A crystalline form of 4- (5-{(1R)-1-[5-(3-chlorophenyl) isoxazol-3- yl]ethoxy}-4-methyl-4H-1,2,4-triazol-3- yl)pyridine. WO019101; 2010
84. AstraZeneca AB and NPS Pharmaceuticals, Inc. 5- (Phenylisoxazolylethoxy)- triazol-3-yl substituted pyridine compounds for the treatment of neurological, psychiatric or pain disorders. WO040982; 2007
85. AstraZeneca AB. Processes for the manufacture of 3-{4-methyl-5-[(1R)-1- (2- (3-methylphenyl)-2H-tetrazol-5-yl)- ethoxy]-4H-[1,2,4]triazol-3-yl}- pyridine, 4-methyl-3-methylthio-5-(3-pyridyl)- 1,2,4-triazole, and (1R)-1[2-(3- methylphenyl)-2H-tetrazol-5-yl]ethanol. WO071559; 2010
86. AstraZeneca AB. Tetrazole derivatives as modulators of metabotropic glutamate receptors (mGluRs). WO051556; 2009
87. F. Hoffman-LaRoche AG. Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists. WO019989; 2012
88. F. Hoffman-LaRoche AG. Pharmaceutical compositions of metabotropic glutamate 5 receptor (mGlu5) antagonists. WO019990; 2012
89. Merz Pharma GmbH & Co. KGaA. Enteric formulations of metabotropic glutamate receptor modulators. WO139876; 2012
90. Merz Pharma GmbH & Co. KGaA. Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine. WO015269; 2008
91. Merz Pharma Press Release. Positive results of the phase I study for treatment of late complications in Parkinson's disease. Frankfurt: 2011. Available from: http://www.autismtherapeutics.com/? p=238
92. Merz Pharma GmbH & Co. KGaA. Pyrazolopyrimidines, a process for their preparation and their use as medicine. WO063487; 2010
93. Merz Pharma GmbH & Co. KGaA. Metabotropic glutamate receptor modulators. WO052451; 2012
94. Gasparini F, Andres H, Flor PJ, et al. Kuhn R. [3H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. Bioorg Med Chem Lett 2002;12:407-9
95. Santana L, Gonzalez-Diaz H, Quezada E, et al. Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. J Med Chem 2008;51:6740-51
96. Wyeth LLC. Bisaryl alkynylamides as negative allosteric modulators of metabotropic glutamate receptor 5 (mGluR5). WO124047; 2010
97. F. Hoffman-LaRoche AG. Imidazole derivatives as mGluR5 antagonists. WO006910; 2011
98. Recordati Ireland, Ltd. Novel spiroheterocyclic compounds as mGlu5 antagonists. WO004400; 2012
99. Guarneri L, Cova R, Angelico P, et al. Effects of different drugs on the cystometrogram in conscious rats. Pharmacol Res 1991;24:175-87
100. AstraZeneca AB. Sulphide bridged derivatives as modulators of mGluR5. WO123451; 2010
101. Richter Gedeon Nyrt. Thieno[2,3-beta] pyridine compounds with mGluR activity. WO001185;2010
102. Richter Gedeon Vegyeszeti Gyar Rt. New compounds. WO072095; 2007
103. Vogel JR, Beer B, Cloudy DE. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacology (Berl) 1971;21:1-7
104. Glaxo Group, Ltd. Tricyclic compounds as glutamate receptor modulators. WO049366; 2010
105. Glaxo Group, Ltd. Novel compounds. WO151361; 2011
106. H. Lundbeck A/S. Adamantyl diamide derivatives and uses of same. WO011570; 2010
107. H. Lundbeck A/S. Adamantyl derivatives and uses of same. WO087758; 2011
108. Cosford NDP, Roppe J, Tehrani L, et al. [3H]-Methoxymethyl-MTEP and [3H]- methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg Med Chem Lett 2003;13:351-4
109. O'Brien JA, Lemaire W, Chen T-B, et al. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol Pharmacol 2003;64:731-40
110. Njung'e K, Handley SL. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 1991;38:63-7
111. Moore NA, Rees G, Sanger G, Tye NC. Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 1994;5:196-202
112. Cryan JF, Valentino RJ, Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 2005;29:547-69
113. Lundbeck A/S. Bicyclo[3.2.1]octyl amide derivatives and uses of same. WO088365; 2012
114. Merz Pharma GmbH & Co. KGaA. Metabotropic glutamate receptor modulators. WO085166; 2012
115. Merz Pharma GmbH & Co. KGaA. Metabotropic glutamate receptor modulators. WO085167; 2012
116. Recordati Ireland, Ltd. Heterocyclic derivatives as m-Glu5 antagonists. WO089119;2010
117. Recordati Ireland, Ltd. Heterocyclic mGlu5 antagonists. WO029633; 2011
118. F. Hoffman-LaRoche AG. Pyridine-2-ylcarboxylic acid amides. WO100050; 2010
119. Sepracor, Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5 and methods of use therof. WO 114971; 2010
120. Burdi DF, Hunt R, Fan L, et al. Design, synthesis, and structure-activity relationships of novel bicyclic azole-amines as negative allosteric modulators of metabotropic glutamate receptor 5. J Med Chem 2010;53:7107-18
121. Vanderbilt Univ. Substituted heteroarylamine carboxamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same. WO035174; 2011
122. Vanderbilt Univ. Substituted heteroarylamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same. WO035186; 2011
123. Vanderbilt Univ. Substituted benzamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same. WO035209; 2011
124. Vanderbilt Univ. Substituted phenylamine carboxamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same. WO035214; 2011
125. Vanderbilt Univ. 6-Alkyl-N-(pyridin-2- yl)-4-aryloxypicolinamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same. WO118563; 2012
126. Deacon RMJ. Digging and marble burying in mice: simple methods for in vivo identification of biological impacts. Nat Protoc 2006;1:122-4
127. Thomas AM, Bui N, Perkins JR, et al. Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome. Psychopharmacology (Berl) 2012;219:47-58
128. Brocke KS, Staufner C, Luksch H, et al. Glutamate receptors in pediatric tumors of the central nervous system. Cancer Biol Ther 2010;9:455-68
129. Teh J, Chen S. Metabotropic glutamate receptors and cancerous growth. WIREs Membr Transp Signal 2012;1:211-20
130. Chen Y, Goudet C, Pin JP, Conn PJ. N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro- 2H-isoindol-2-yl)methyl]phenyl}-2- hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Mol Pharmacol 2008;73:909-18
131. Rodriguez AL, Nong Y, Sekaran NK, et al. A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Mol Pharmacol 2005;68:1793-802